Publications

  • Wermeling DP, Record KA, Kelly TH, Archer SM, Clinch T, Rudy AC. Pharmacokinetics and pharmacodynamics of a new intranasal midazolam folmulation in healthly volunteers. Anesth Analg 2006; 103:344-349.
  • Wermeling DP, Miller JL, Archer SM, Rayens MK, Rudy AC. Pharmacokinetics, Bioequivalence, and Spray Weight Reproducibility of Intranasal Butorphanol After Administration with 2 Different Nasal Spray Pumps. J Clin Pharmacol 2005;45:969-973.
  • Wermeling DP, Grant GM, Lee A, Alexander N, Rudy AC. Analgesic effects of intranasal butorphanol tartrate administered via a unit-dose device in the dental impaction pain model: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2005;27(4):430-440.
  • Davis GA, Rudy AC, Archer SM, Wermeling DP. Bioavailability of intranasal Butorphanol administered from a single-dose sprayer. Am J Health Syst Pharm 2005;62:48-53.
  • Davis GA, Rudy AC, Archer SM, Wermeling DP, McNamara PJ. Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis. Clin Drug Invest 2004;24(11):633-639.
  • Rudy AC, Coda BA, Archer SM, Wermeling DP. A Multiple-dose phase 1 study of intranasal Hydromorphone hydrochloride in healthy volunteers. Anesth Analg 2004;99:1379-1386.
  • Davis GA, Rudy AC, Archer SM, Wermeling DP, McNamara PJ. Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. Pharmacotherapy 2004;24(1):26-32.
  • Davis GA, Rudy AC, Archer SM, Wermeling DP. Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer. Am J Health Syst Pharm 2004;61(2):261-266.
  • Edwards JE, Rudy AC, Wermeling DP, Desai N, McNamara PJ. Hydromorphone transfer into breast milk after intranasal administration. Pharmacotherapy 2003;23(2):153-158.
  • Coda BA, Rudy AC, Archer SM, Wermeling DP. Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesth Analg 2003;97:117-123.
  • Wermeling DP, Miller JL, Rudy AC. Systemic intranasal drug delivery: concepts and application. Drug Delivery Technology 2002;2:56-61.
  • Wermeling DPH, Miller JL, Archer SM, Manaligod JM, Rudy AC. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J Clin Pharmacol 2001;41:1225-1231.
Book Chapters
  • Wermeling DP, Miller JL.  Intranasal Drug Delivery. In: Rathbone MJ, Hadgraft J, Roberts MS, eds. Modified-Release Drug Delivery Technology. New York, NY: Marcel Dekker; 2002:727-748.
BACK TO TOP
Abstracts
  • Paudel K, Valiveti S, Agu R, Hammell D, Earles DC, Wermeling D, Stinchcomb A. Intranasal absorption of delta9-tetrahydrocannabinol and win 55,212-2 mesylate in rats. The AAPS Journal 2004;6(4), Abstract W4267. Available at http://www.aapspharmaceutica.com/
  • Rudy AC, Wermeling DP. Pilot dose-ranging study of unit dose intranasal butorphanol tartrate in dental pain model. Presented at 2003 AAPS Annual Meeting.  AAPS PharmSci 2003;5(4), Abstract W4185. Available at http://www.aapspharmsci.org/
  • Davis GA, Rudy AC, Archer SM, Wermeling DP.  Bioavailability of intranasal butorphanol using unit-dose sprayers in healthy volunteers. Presented at 31st (2002) Annual Meeting of American College of Clinical Pharmacology. J Clin Pharmacol 2002;42:1058. Abstract 35. Presented at American College of Clinical Pharmacy 2002 Annual Meeting. Encore poster. Pharmacotherapy 2002;22(10):1363. Abstract 249E.
  • Davis GA, Rudy AC, Wermeling DP, Archer SM.  Single and multiple dose pharmacokinetics of 1.0 mg or 2.0 mg of intranasal butorphanol tartrate using single dose sprayers in healthy volunteers. Presented at 2002 American Society of Health-System Pharmacists Midyear Clinical Meeting. Int Pharmaceut Abst November 2002;39(21):2270-2271. Abstract P-446E.
  • Rudy AC, Record KE, Archer SM, Wermeling DP.  Bioavailability and pharmacokinetics of intranasal midazolam. Presented at 2002 AAPS Annual Meeting. AAPS PharmSci 2002;4(4). Abstract W4175. Available at http://www.aapspharmsci.org/
  • Wermeling DP, Miller JL, Archer SM, Manaligod J, Rudy AC. Pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. Presented at American College of Clinical Pharmacy 2001 Spring Practice and Research Forum. (Finalist Best Poster Award Competition).
  • Rudy AC, Wermeling D, Coda BA, Jay M, Archer S. Pharmacokinetics (PK) and bioavailability of hydromorphone HCl (HM HCl) after intranasal (IN) and intravenous (IV) administration. Presented at 2001 AAPS Annual Meeting. AAPS PharmSci 2001;3(3). Abstract T3742. Available at http://www.aapspharmsci.org/
  • McNamara PJ, Davis GA, Miller JL, Rudy AC, Wermeling DP.  Bioavailability and pharmacokinetics of intranasal hydromorphone in treated and untreated allergic rhinitis patients. Presented at American College of Clinical Pharmacy 2001 Annual Meeting. Pharmacotherapy 2001;21(10):1265.
  • Edwards JE, Rudy A, Wermeling D, McNamara PJ.  The distribution of hydromorphone into human milk. Presented at 2001 AAPS Annual Meeting. AAPS PharmSci 2001;3(3). Abstract T3404. Available at http://www.aapspharmsci.org/
  • Rudy AC, Wermeling DP, Archer SM, Rayens MK, Jay M.  Accuracy of intranasal (IN) butorphanol tartrate (BT) delivery in 2 nasal spray pumps used in clinical study.  Presented at 2000 AAPS Annual Meeting. AAPS PharmSci 2000;2(2). Abstract 913. Available at http://www.aapspharmsci.org/
BACK TO TOP